Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity
Amit A Joharapurkar, Nirav A Dhanesha, Mukul R Jain Department of Pharmacology and Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad, India Abstract: Worldwide prevalence of obesity has nearly doubled since 1980. Obesity is the result of interactions among the environmental f...
Guardado en:
Autores principales: | Joharapurkar AA, Dhanesha NA, Jain MR |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1cfb07d69eeb45deaa87a8b0f73ea83c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander PA
Publicado: (2012) -
Causes and consequences of obesity: epigenetics or hypokinesis?
por: Graham MR, et al.
Publicado: (2015) -
The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
por: Sonia A Tucci, et al.
Publicado: (2010) -
Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
por: B Shariat-Madar, et al.
Publicado: (2010) -
Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Lisa M Neff, et al.
Publicado: (2010)